Calculus injects £2.5m into Axol Bioscience

The fresh capital will be used to grow and develop more product lines as well as to expand its sales and marketing operations.

Funding for the deal came from Calculus Capital's EIS Fund, which typically invests for large minority stakes. The VC is also the only institutional investor, with the remainder of the company owned by individuals. Calculus's Alexandra Lindsay will join the board of the company.

In 2016, Axol generated turnover of £561,265, almost double the previous year's result, and made a loss of £715,742 due to large administrative expenses.

Company
Established in 2012, Axol provides stem cells to pharmaceutical companies and research institutions, including Harvard University, King's College London, and Oxford and Cambridge Universities. The company generates stem cells from blood and tissue cells extracted from healthy and diseased patients.

People
Calculus Capital – Alexandra Lindsay (investment director).
Axol Biosciences – Jonathan Milner (co-founder); Yichen Shi (co-founder & CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• UK / Ireland
• Healthcare
• Calculus Capital
• United Kingdom